EPM develops prescription medicine derived from synthetic cannabinoid acids to address unmet patient needs. The company has created a pipeline that includes the discovery of 14 protected synthetic molecules, including eight novel structures and production process intellectual property. Currently, EPM's focus is on two main therapeutic conditions: metabolic disorders (Prader-Willi syndrome) and inflammatory skin disease (psoriasis).